Business Model Breakdown
How Health In Tech Inc Makes Money
HIT
Market Cap
$82M
Annual Revenue
$33M
Profit Margin
3.8%
Employees
73
The Short Version
Health In Tech (HIT) operates an AI-driven digital health platform that offers personalized preventive care solutions. The company partners primarily with employers to provide their employees with customized health programs, tools, and insights aimed at improving long-term health outcomes and reducing healthcare costs. This subscription-based model allows employers to offer cutting-edge health benefits to their workforce while creating a scalable revenue stream for HIT.
Where the Revenue Comes From
Subscription fees from employers for platform access and services (estimated ~90%)
Potential future data insights/licensing (early stage)
Who buys: Primarily enterprise clients (employers) seeking to provide health benefits and improve employee wellness, indirectly serving their employees.
Why It Works (Competitive Advantages)
- ✔AI-driven personalized preventive care model targeting long-term health outcomes.
- ✔Developing a proprietary data moat from enrolled employee engagement.
- ✔Focus on employer-based contracts provides scalable distribution channel.
Economic Moat: Narrow (Intangible Assets/IP (proprietary AI algorithms, data analytics), Switching Costs (for employers integrating their platform into benefits), Network Effects (potential with increasing data leading to better outcomes and more users))
What Our Analysis Says
DVR Score as of April 18, 2026
Health In Tech (HIT) continues to exhibit strong 10x growth potential, validated by its Q4 and full-year 2025 results, which showed a significant 71% YoY revenue increase to $33.3 million and, critically, achieved full-year net profitability of $1.3 million. This transition from 'unprofitable' status is a material positive development, demonstrating execution on its AI-driven personalized preventive care vision within the expansive digital health market. The recently closed $7.0 million private placement further strengthens its financial runway. While Q4 saw a slight net loss, the overall financial trajectory is positive. Major enterprise contracts and broader clinical validation remain key catalysts for future re-rating, with inherent risks in execution and competition in a highly dynamic sector. The score reflects improved financial fundamentals and continued strategic progress.